BridgeBio Pharma LLC, 10% Owner at Eidos Therapeutics, Inc. (EIDX), bought 80,144 shares at $13.34 ($1.1M) on 2018-12-06, disclosed to the SEC on 2018-12-13.
Open-market purchase of $1.1M EIDX by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.34 | 38,970 | $520K | 47.4% |
| 2 | $13.94 | 36,314 | $506K | 46.2% |
| 3 | $14.36 | 4,860 | $70K | 6.4% |
| Total | $13.67 avg | 80,144 | $1.1M | 100% |
| Filing → |
| EIDX | BUY | 2018-12-13 | $542K | — | Filing → |
| EIDX | SELL | 2018-12-12 | $542K | — | Filing → |
| EIDX | SELL | 2018-12-10 | $1.1M | — | Filing → |